4-Isothiocyanatopiperidine | 1092833-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Isothiocyanatopiperidine
• CAS: 1092833-29-8
• 化学式: C₆H₁₀N₂S
• 分子量: 142.225
• InChiKey: PYECMAVHMMXGMT-UHFFFAOYSA-N

物化性质

• 沸点：
  250.1±29.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Isothiocyanatopiperidine 、 3,5-二甲基吡唑-1-硝酸咪 以 N,N-二甲基甲酰胺 为溶剂， 生成 3,5-dimethyl-N-(piperidin-4-ylcarbamothioyl)-1H-pyrazole-1-carboximidamide
  参考文献：
  名称：

  Structure–activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors

  摘要：

  Cdk5/p25 has emerged as a principle therapeutic target for numerous acute and chronic neurodegenerative diseases, including Alzheimer's disease. A structure-activity relationship study of 2,4-diaminothiazole inhibitors revealed that increased Cdk5/p25 inhibitory activity could be accomplished by incorporating pyridines on the 2-amino group and addition of substituents to the 2- or 3-position of the phenyl ketone moiety. Interpretation of the SAR results for many of the analogs was aided through in silico docking with Cdk5/p25 and calculating protein hydrations sites using WaterMap. Finally, improved in vitro mouse microsomal stability was also achieved. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.140

文献信息

• Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
  申请人：Binggeli Alfred

  公开号：US20060205718A1

  公开（公告）日：2006-09-14

  This invention is concerned with compounds of the formula wherein A, B 1 , B 2 , R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A、B 1 、B 2 、R 1 、R 2 和G如描述和索赔中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Isoprenyl-thiourea and urea derivatives as new farnesyl diphosphate analogues: Synthesis and in vitro antimicrobial and cytotoxic activities
  作者：José M. Vega-Pérez、Ignacio Periñán、Montserrat Argandoña、Margarita Vega-Holm、Carlos Palo-Nieto、Estefanía Burgos-Morón、Miguel López-Lázaro、Carmen Vargas、Joaquín J. Nieto、Fernando Iglesias-Guerra

  DOI：10.1016/j.ejmech.2012.10.042

  日期：2012.12

  A series of new isoprenyl-thiourea and urea derivatives were synthesized by the reaction of alkyl or aryl isothiocyanate or isocyanate and primary amines. The structures of the compounds were established by 1H NMR, 13C NMR, MS, HRMS and elemental analysis. The new compounds were screened for in vitro antimicrobial activity against seven strains representing different types of gram-positive and gram-negative

  通过烷基或芳基异硫氰酸酯或异氰酸酯与伯胺的反应，合成了一系列新的异戊二烯基-硫脲和脲衍生物。化合物的结构通过1 H NMR，13 C NMR，MS，HRMS和元素分析确定。对新化合物进行了体外筛选对代表不同类型革兰氏阳性和革兰氏阴性细菌的七种菌株的抗菌活性。超过三分之一的合成化合物显示出对测试菌株的可变抑制活性。对于具有3-甲基-2-丁烯基，异丁基或异戊基和具有吸电子取代基的芳环的那些硫脲类似物，发现了最佳的抗菌活性。还对新化合物进行了抗肿瘤活性的初步筛选。芳环中高度亲脂性基团和吸电子基团的存在增强了合成化合物的抗癌活性，在大多数情况下显示出比对照更高的活性。
• Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases
  作者：Ernst Schonbrunn、Stephane Betzi、Riazul Alam、Mathew P. Martin、Andreas Becker、Huijong Han、Rawle Francis、Ramappa Chakrasali、Sudhakar Jakkaraj、Aslamuzzaman Kazi、Said M. Sebti、Christopher L. Cubitt、Anthony W. Gebhard、Lori A. Hazlehurst、Joseph S. Tash、Gunda I. Georg

  DOI：10.1021/jm301234k

  日期：2013.5.23

  Cyclin-dependent kinases (CDKs) are serine/threonine protein kinases that act as key regulatory elements in cell cycle progression. We describe the development of highly potent diaminothiazole inhibitors of CDK2 (IC50 = 0.0009-0.0015 mu M) from a single hit compound with weak inhibitory activity (IC50 = 15 mu M), discovered by high-throughput screening. Structure-based design was performed using 35 cocrystal structures of CDK2 liganded with distinct analogues of the parent compound. The profiling of compound 51 against a panel of 339 kinases revealed high selectivity for CDKs, with preference for CDK2 and CDK5 over CDK9, CDK1, CDK4, and CDK6. Compound 51 inhibited the proliferation of 13 out of 15 cancer cell lines with IC50 values between 0.27 and 6.9 mu M, which correlated with the complete suppression of retinoblastoma phosphorylation and the onset of apoptosis. Combined, the results demonstrate the potential of this new inhibitors series for further development into CDK-specific chemical probes or therapeutics.
• N-Heterocyclyl-4-piperidinamines, methods for their preparation, pharmaceutical compositions comprising them, intermediates therefor, and method for the preparation of the intermediates
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0005318B1

  公开（公告）日：1982-01-06
• BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1858901A1

  公开（公告）日：2007-11-28